CClinicalTrials.gg
Sign In
CompletedNCT01543386CURCUMINUpdated Aug 5, 2026

Effects of Curcumin on Vascular Reactivity

A Phase 1/2 interventional study of Curcumin in Healthy Volunteers (Middle-aged Smokers), sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 50 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by University Hospital, Clermont-Ferrand · Phase 1/2, Interventional, and Treatment

Phase
Phase 1/2
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
All
01

Study summary

The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk

Read the detailed description

The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk

02

Conditions studied

  • Healthy Volunteers (Middle-aged Smokers)

Browse trials for

Keywords

  • Polyphenol
  • Curcumin
  • Endothelium, vascular
  • Endothelium-dependant relaxing factor
  • Smoking
  • Transcriptome
03

In context

Smoking

268 studies on the registry are indexed under Smoking; 136 are open to participants now.

This study's enrollment of 21 is below the median of 120 across 211 interventional studies indexed under Smoking.

Browse Smoking studies →

Lead sponsor

University Hospital, Clermont-Ferrand is the lead sponsor of 841 studies on the registry; 178 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 50 to 70 year-old volunteers
  • smokers

Exclusion criteria

Exclusion Criteria:

  • treated hypertension
  • treated hypercholesterolemia
  • chronic disease
  • vegetarian or other unusual diets
  • chronic alcoholism
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
21 participants (actual)

Study arms

  • Other
    curcumin

    The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk

    Drug: Curcumin

Interventions

  • DrugCurcumin

    The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk

06

What researchers measure

Primary outcomes

  1. Changes in brachial Flow Mediated Dilatation

    Time frame: at Visit 1 (Day 0) and visit 2 (Day3/day5)

Secondary outcomes

  1. Changes in fingertip arterial tonometry

    Time frame: at visit 1 (day 0) and visit 2 (day3/day5)

  2. Modifications of leukocytes transcriptome

    Time frame: at visit 1 (day 0) and visit 2 (day3/day 5)

07

Study locations

1 site
  • CHU Clermont-Ferrand
    Clermont-Ferrand, 63003, France
08

References and documents

Publications

  • Barber-Chamoux N, Milenkovic D, Verny MA, Habauzit V, Pereira B, Lambert C, Richard D, Boby C, Mazur A, Lusson JR, Dubray C, Morand C. Substantial Variability Across Individuals in the Vascular and Nutrigenomic Response to an Acute Intake of Curcumin: A Randomized Controlled Trial. Mol Nutr Food Res. 2018 Mar;62(5). doi: 10.1002/mnfr.201700418. Epub 2018 Feb 12. PubMed 29034576 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01543386
Lead sponsor
University Hospital, Clermont-Ferrand
Collaborators
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement, Association Régionale de Cardiologie d'Auvergne, ARDEC Association de Recherche de Développement et d'Enseignement de la Cardiologie
Responsible party
Sponsor
First posted
Mar 5, 2012
Start date
Feb 2012
Primary completion
Apr 2012
Completion
Apr 2012
Last update
Aug 5, 2026

Study contacts

Jean-René LUSSON
principal investigator · University Hospital, Clermont-Ferrand
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Smoking→

Other studies from this sponsor

University Hospital, Clermont-Ferrand

Start the discussion